SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80: 15881594.
  • 2
    McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs. 2001; 61: 12531274.
  • 3
    Coleman RE, Rubens RD. Bone metastases. In: AbeloffMD, ArmitageJO, NiederhuberJE, KastanMB, McKennaWG, eds. Clinical Oncology. 3rd ed. New York: Churchill Livingstone; 2004: 10911128.
  • 4
    Pelger RC, Soerdjbalie-Maikoe V, Hamdy NA. Strategies for management of prostate cancer-related bone pain. Drugs Aging. 2001; 18: 899911.
  • 5
    Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005; 16: 579584.
  • 6
    Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005; 23: 33143321.
  • 7
    Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 14581468.
  • 8
    Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100: 26132621.
  • 9
    Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005: CD003474.
  • 10
    Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003; 21: 40424057.
  • 11
    Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002; 20: 37193736.
  • 12
    Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16: 20382044.
  • 13
    Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of 2 randomized, placebo-controlled trials. Cancer. 2000; 88: 10821090.
  • 14
    Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999; 17: 846854.
  • 15
    Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98: 17351744.
  • 16
    Zheng M, Rosen LS, Gordon D, et al. Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases [abstract]. Breast. 2005; 14: S44.
  • 17
    Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96: 879882.
  • 18
    Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002; 168: 10051007.
  • 19
    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7: 377387.
  • 20
    Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21: 31503157.
  • 21
    Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998; 16: 593602.
  • 22
    Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol. 2004; 46: 731739, discussion 739–740.
  • 23
    Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc. 2003; 51: 364370.
  • 24
    O'Neill TW, Roy DK. How many people develop fractures with what outcome? Best Pract Res Clin Rheumatol. 2005; 19: 879895.
  • 25
    Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB. Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. J Nephrol. 2005; 18: 458463.
  • 26
    Truumees E. Medical consequences of osteoporotic vertebral compression fractures. Instr Course Lect. 2003; 52: 551558.
  • 27
    Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004; 6: 170174.
  • 28
    Jalava T, Sarna S, Pylkkanen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res. 2003; 18: 12541260.
  • 29
    Kado DM, Duong T, Stone KL, et al. Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int. 2003; 14: 589594.
  • 30
    Bauer HC. Controversies in the surgical management of skeletal metastases. J Bone Joint Surg Br. 2005; 87: 608617.
  • 31
    Saba N, Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2. Clinical studies and economic analyses. Oncology. 2005; 68: 1822.
  • 32
    Coleman RE. Bisphosphonates in breast cancer. Ann Oncol. 2005; 16: 687695.
  • 33
    Gulley J, Dahut WL. Clodronate in the prevention and treatment of skeletal metastasis. Expert Rev Anticancer Ther. 2005; 5: 221230.
  • 34
    Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of GCP 42′466, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994; 9: 747751.